Media Release

QIAGEN supports Singapore's National Precision Medicine Program with sample preparation and Next-Generation Sequencing technologies

- **QIAsprint Connect to automate DNA extraction and QIAseq FX DNA Library Kit to provide automated library preparation for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine program**

- **Phase III expands the national precision medicine effort to about 450,000 residents as genomics moves from research cohorts toward integration into clinical workflows**

- **Project marks QIAGEN's first deployment of universal Next-Generation Sequencing technologies for a population genomics initiative**

Venlo, the Netherlands, and Singapore, Singapore, November 3, 2026 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAsprint Connect and QIAseq FX DNA Library Kit will support automated DNA extraction and library preparation for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) program, as part of a consortium led by Singapore-based precision oncology leader Lucence alongside sequencing pioneer Ultima Genomics.

Coordinated by Precision Health Research, Singapore (PRECISE), NPM Phase III expands Singapore's national precision medicine effort to about 450,000 residents – around 10% of the Singapore resident population – with a shift towards enrolling participants who are receiving medical treatment and healthcare services. Unlike Phase II, which focused on healthy volunteers, Phase III includes patients across a wide spectrum of health conditions through Singapore's three public healthcare clusters, supporting the longer-term goal of moving genomics from research cohorts towards integration into clinical workflows and national healthcare delivery.

"Population genomics is increasingly moving closer to clinical care, placing new demands on the reliability, consistency and scalability of the workflows that underpin whole genome sequencing," said Justus Krause-Harder, Head of Molecular Tools & Oncology at QIAGEN. "SG-INSIGHT demonstrates the scale at which these capabilities are now required. QIAGEN is pleased to contribute our expertise in automated sample preparation and help support the operational requirements of clinical-grade whole genome sequencing at national scale."

QIAGEN will provide an automated, single-source sample-to-library workflow that guarantees data consistency from biological intake to downstream analysis:

- Marking its first national-scale deployment, **QIAsprint Connect** automates genomic DNA extraction for high-throughput applications and can perform two automated runs of up to 96 samples each from a single start command, delivering a peak capacity of more than 3,600 samples per week. Built-in barcode checks prevent setup errors, while automated audit trails and run reports strengthen traceability and compliance. Its compact footprint and high functional density bring high-throughput automation into less bench space, helping laboratories scale their operations efficiently.

- Following DNA extraction, the **QIAseq FX DNA Library Kit** provides high-fidelity, unbiased library preparation, providing samples ready for sequencing on Ultima Genomics' UG200™ platform. Its all-in-one reaction minimizes sample transfers and consumable tip usage. Its advanced enzymatic chemistry delivers uniform coverage across challenging GC-rich genomic regions, ensuring superior variant calling accuracy and reproducibility.

The SG-INSIGHT project expands QIAGEN's involvement in large-scale population genomics initiatives globally. It is the first time that its universal Next-Generation Sequencing products are deployed in a nationwide population genomics study.

The SG-INSIGHT sequencing work brings together QIAGEN's sample preparation technologies with sequencing services delivered through a consortium led by Singapore-headquartered precision oncology company Lucence and involving Ultima Genomics. Lucence provides program management and laboratory execution, while Ultima Genomics provides high-throughput sequencing technology through its UG200 platform and Solaris 2.0 chemistry.

For QIAGEN, the project underscores the growing role of automated sample preparation as population genomics initiatives increase in scale and move toward clinical applications. By integrating high-throughput DNA extraction and sequencing library preparation, QIAGEN aims to help laboratories meet the operational requirements of large-scale genomic workflows with greater automation, consistency and efficiency.

About PRECISE

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore's multi-phase National Precision Medicine (NPM) program. Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.

PRECISE is a program of the Consortium for Clinical Research and Innovation, Singapore. NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).

www.npm.sg

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "plan", "intend", "seek", "may", "will", "could", "should", "would", "expect", "anticipate", "estimate", "continue", "target" or other similar words. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F. For further information, please refer to QIAGEN's filings with the U.S. Securities and Exchange Commission.

Contacts QIAGEN:

Public Relations
e-mail: pr@QIAGEN.com

Investor Relations
e-mail: ir@QIAGEN.com